ASX:MYXMayne Pharma Group Stock Price, Forecast & News

A$0.42

+0.03 (+7.59 %)

(As of 05/12/2020)

Add

Compare

Today's Range

A$0.41

Now: A$0.43▼

A$0.43

50-Day Range

A$0.32

MA: A$0.40▼

A$0.43

52-Week Range

A$0.20

Now: A$0.43▼

A$0.65

Volume5.47 million shs

Average Volume6.32 million shs

Market Capitalization$713.60 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products worldwide. It operates through four segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. The company also offers oral drug delivery systems; and contract development and manufacturing services to third-party customers. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited is based in Salisbury South, Australia.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Mayne Pharma Group.

2.7 Community Rank

Outperform Votes
Mayne Pharma Group has received 63 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Mayne Pharma Group has received 53 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Mayne Pharma Group has received 54.31% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Mayne Pharma Group and other stocks. Vote “Outperform” if you believe MYX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MYX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Mayne Pharma Group does not currently pay a dividend.
Dividend Growth
Mayne Pharma Group does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Mayne Pharma Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought A$983,621.00 in company stock and sold A$0.00 in company stock.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Mayne Pharma Group are expected to decrease by -100.00% in the coming year, from A$0.05 to A$0.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Mayne Pharma Group is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Mayne Pharma Group is -2.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Mayne Pharma Group has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.27 out of 5 stars

Industry, Sector and Symbol

Stock Exchange ASX

Industry Drug Manufacturers - Major

Sub-IndustryN/A

SectorMedical

Current SymbolASX:MYX

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.maynepharma.com

Phone+61-8-82092666

Debt

Debt-to-Equity Ratio35.56

Current Ratio2.21

Quick Ratio1.60

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E Ratio8.60

P/E GrowthN/A

Sales & Book Value

Annual Sales$477.99 million

Price / Sales1.49

Cash FlowA$0.06 per share

Price / Cash Flow7.20

Book ValueA$0.65 per share

Price / Book0.65

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees780

Outstanding Shares1,679,069,952

Market Cap$713.60 million

Next Earnings Date8/21/2020 (Estimated)

OptionableNot Optionable

Receive MYX News and Ratings via Email

Sign-up to receive the latest news and ratings for MYX and its competitors with MarketBeat's FREE daily newsletter.

Mayne Pharma Group (ASX:MYX) Frequently Asked Questions

How has Mayne Pharma Group's stock been impacted by COVID-19 (Coronavirus)?

Mayne Pharma Group's stock was trading at A$0.29 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MYX stock has increased by 49.1% and is now trading at A$0.43. View which stocks have been most impacted by Coronavirus.

When is Mayne Pharma Group's next earnings date?

Mayne Pharma Group is scheduled to release its next quarterly earnings announcement on Friday, August 21st 2020. View our earnings forecast for Mayne Pharma Group.

How were Mayne Pharma Group's earnings last quarter?

Mayne Pharma Group Ltd (ASX:MYX) announced its quarterly earnings data on Friday, February, 22nd. The company reported $0.02 earnings per share (EPS) for the quarter. View Mayne Pharma Group's earnings history.

Has Mayne Pharma Group been receiving favorable news coverage?

Media headlines about MYX stock have trended positive on Saturday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mayne Pharma Group earned a news sentiment score of 2.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutMayne Pharma Group.

Who are some of Mayne Pharma Group's key competitors?

Some companies that are related to Mayne Pharma Group include Hutchison China MediTech (HCM), Opthea (OPT), Vectura Group (VEC), Medical Developments International (MVP), BEXIMCO PHARMAC/S GDR REGS (BXP), Eco Animal Health Group (EAH), Trilogy International Partners (TRL), Allergy Therapeutics (AGY), Recce Pharmaceuticals (RCE), Futura Medical (FUM), NanoViricides (NNVC), Vita Life Sciences (VLS), Pharmaxis (PXS), Avivagen (VIV) and Antisense Therapeutics (ANP). View all competitors.

What other stocks do shareholders of Mayne Pharma Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mayne Pharma Group investors own include SUNDANCE ENERGY/S (SNDE), Aurora Cannabis (ACB), Turquoise Hill Resources (TRQ), Telstra (TLS), Green Organic Dutchman (TGODF), Perseus Mining (PRU), OrganiGram (OGI), Karoon Energy (KAR), Crown Resorts (CWN) and Cronos Group (CRON).

Who are Mayne Pharma Group's key executives?

Mayne Pharma Group's management team includes the following people:

Mr. Scott Anthony Richards, MD, CEO & Exec. Director (Age 55)
Mr. Nick Freeman BCom, CA, Group CFO & Company Sec.
Mr. Stefan J. Cross, Pres of International Operations (Age 46)
Dr. Ilana Stancovski, Chief Scientific Officer & Head of European Market Devel.
Ms. Lisa Pendlebury, VP of Investor Relations & Communications

What is Mayne Pharma Group's stock symbol?

Mayne Pharma Group trades on the ASX under the ticker symbol "MYX."

What is Mayne Pharma Group's stock price today?

One share of MYX stock can currently be purchased for approximately A$0.43.

How big of a company is Mayne Pharma Group?

Mayne Pharma Group has a market capitalization of $713.60 million and generates $477.99 million in revenue each year. Mayne Pharma Group employs 780 workers across the globe.

What is Mayne Pharma Group's official website?

The official website for Mayne Pharma Group is www.maynepharma.com.

How can I contact Mayne Pharma Group?

Mayne Pharma Group's mailing address is 1538 Main North Rd, ADELAIDE, SA 5106, Australia. The company can be reached via phone at +61-8-82092666.

This page was last updated on 6/6/2020 by MarketBeat.com Staff